Glazier James J, Kaki Amir
Department of Cardiology, Wayne State University/Detroit Medical Center, Heart Hospital, Detroit, Michigan.
Int J Angiol. 2019 Jun;28(2):118-123. doi: 10.1055/s-0038-1676369. Epub 2018 Dec 20.
The Impella device is a catheter-based miniaturized ventricular assist device. Using a retrograde femoral artery access, it is placed in the left ventricle across the aortic valve. The device pumps blood from left ventricle into ascending aorta and helps to maintain a systemic circulation at an upper rate between 2.5 and 5.0 L/min. This results in almost immediate and sustained unloading of the left ventricle, while increasing overall systemic cardiac output. The most common indications for using the Impella device are in the treatment of acute myocardial infarction complicated by cardiogenic shock and to facilitate high risk coronary angioplasty. Other indications include the treatment of cardiomyopathy with acute decompensation, postcardiotomy shock, and off-pump coronary bypass surgery. A growing body of observational and registry data suggest a potentially valuable role for the Impella system in reducing the mortality associated with cardiogenic shock. However, there are, as of yet, no randomized controlled trial data supporting this observation.
Impella装置是一种基于导管的小型心室辅助装置。通过逆行股动脉入路,将其经主动脉瓣置于左心室内。该装置将血液从左心室泵入升主动脉,并有助于维持2.5至5.0升/分钟的较高速率的体循环。这几乎能立即且持续地减轻左心室的负荷,同时增加整体体循环心输出量。使用Impella装置最常见的适应症是治疗并发心源性休克的急性心肌梗死以及促进高风险冠状动脉血管成形术。其他适应症包括治疗急性失代偿性心肌病、心脏术后休克和非体外循环冠状动脉搭桥手术。越来越多的观察性和登记数据表明,Impella系统在降低与心源性休克相关的死亡率方面可能具有重要作用。然而,截至目前,尚无随机对照试验数据支持这一观察结果。